| 0 | 💬 0 |
Rituximab versus Ocrelizumab in Newly Diagnosed Relapsing Multiple Sclerosis.
(nejm.org)
|
New England Journal of Medicine 2026-07-02 | #multiple sclerosis #antibody #clinical trial #immunotherapy #autoimmunity |